Get startedLog in
    Picture of Lexicon Pharmaceuticals logo

    LXRX — Lexicon Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapMomentum Trap
    All News

    Brief: Lexicon Announces Completion Of Enrollment In Phase 2B Progress Study Of LX9211 In Diabetic Peripheral Neuropathic Pain

    Picture of Lexicon Pharmaceuticals logoLexicon Pharmaceuticals
    26/11/2024 13:06
    Nov 26 (Reuters) - Lexicon Pharmaceuticals Inc  LXRX.O :
    * LEXICON ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2B
PROGRESS
STUDY OF LX9211 IN DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP)
    * LEXICON PHARMACEUTICALS INC - TOP-LINE DATA FROM PROGRESS
STUDY
EXPECTED IN Q1 2025

Source text:  ID:nGNX3M4myF 
Further company coverage:  LXRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Lexicon Pharmaceuticals

    See all news